Equities Analysts Offer Predictions for OCUL Q1 Earnings

Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) - Stock analysts at HC Wainwright issued their Q1 2026 EPS estimates for shares of Ocular Therapeutix in a research report issued to clients and investors on Thursday, May 29th. HC Wainwright analyst Y. Chen expects that the biopharmaceutical company will post earnings per share of ($0.37) for the quarter. HC Wainwright has a "Buy" rating and a $15.00 price objective on the stock. The consensus estimate for Ocular Therapeutix's current full-year earnings is ($0.98) per share. HC Wainwright also issued estimates for Ocular Therapeutix's Q2 2026 earnings at ($0.36) EPS, Q3 2026 earnings at ($0.37) EPS and Q4 2026 earnings at ($0.35) EPS.

A number of other research firms have also weighed in on OCUL. William Blair started coverage on Ocular Therapeutix in a research note on Tuesday, April 8th. They issued an "outperform" rating for the company. JMP Securities set a $19.00 price objective on shares of Ocular Therapeutix in a research note on Tuesday, March 4th. Needham & Company LLC cut their target price on Ocular Therapeutix from $15.00 to $14.00 and set a "buy" rating on the stock in a research note on Tuesday, May 6th. Finally, Royal Bank of Canada started coverage on Ocular Therapeutix in a report on Tuesday, March 18th. They set an "outperform" rating and a $17.00 price target on the stock. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $16.25.

Ocular Therapeutix Price Performance

Shares of NASDAQ OCUL traded up $0.22 during trading hours on Monday, reaching $8.33. 2,951,070 shares of the stock traded hands, compared to its average volume of 1,407,828. Ocular Therapeutix has a 52-week low of $4.79 and a 52-week high of $11.78. The company has a quick ratio of 12.94, a current ratio of 13.01 and a debt-to-equity ratio of 0.19. The company's 50-day simple moving average is $7.38 and its two-hundred day simple moving average is $7.89. The company has a market capitalization of $1.33 billion, a P/E ratio of -6.31 and a beta of 1.51.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last announced its earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.05). The company had revenue of $17.08 million during the quarter, compared to analysts' expectations of $16.89 million. Ocular Therapeutix had a negative return on equity of 45.18% and a negative net margin of 283.74%.

Insider Buying and Selling at Ocular Therapeutix

In related news, insider Pravin Dugel sold 21,219 shares of Ocular Therapeutix stock in a transaction dated Friday, May 23rd. The shares were sold at an average price of $7.18, for a total transaction of $152,352.42. Following the completion of the transaction, the insider now directly owns 3,499,099 shares of the company's stock, valued at $25,123,530.82. This trade represents a 0.60% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Richard L. Md Lindstrom acquired 10,000 shares of the stock in a transaction on Thursday, May 8th. The shares were bought at an average price of $6.96 per share, with a total value of $69,600.00. Following the purchase, the director now directly owns 172,704 shares of the company's stock, valued at $1,202,019.84. The trade was a 6.15% increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders have sold 29,079 shares of company stock valued at $208,739. 2.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Ocular Therapeutix

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Rhumbline Advisers raised its position in shares of Ocular Therapeutix by 4.5% during the 1st quarter. Rhumbline Advisers now owns 223,115 shares of the biopharmaceutical company's stock valued at $1,635,000 after purchasing an additional 9,514 shares during the period. Caxton Associates LLP purchased a new stake in Ocular Therapeutix in the 1st quarter worth $248,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Ocular Therapeutix by 5.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 93,619 shares of the biopharmaceutical company's stock valued at $686,000 after acquiring an additional 5,156 shares during the period. Adage Capital Partners GP L.L.C. lifted its position in shares of Ocular Therapeutix by 44.4% in the first quarter. Adage Capital Partners GP L.L.C. now owns 5,200,000 shares of the biopharmaceutical company's stock valued at $38,116,000 after acquiring an additional 1,600,000 shares in the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of Ocular Therapeutix in the first quarter valued at about $1,011,000. 59.21% of the stock is currently owned by hedge funds and other institutional investors.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.